Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergey Tselmin

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|July 14, 2022
COVID-19 and Lipid DisordersUlrich Julius, Ulrike Schatz, Sergey Tselmin, et al.
Atherosclerosis. Supplements|November 4, 2017
Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulinsSergey Tselmin, Ulrich Julius, Stefan R Bornstein, et al.
Atherosclerosis. Supplements|November 4, 2017
How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single centerBernd Hohenstein, Sergey Tselmin, Stefan R Bornstein, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|September 2, 2022
Correction: COVID-19 and Therapeutic ApheresisSergey Tselmin, Ulrich Julius, Natalia Jarzebska, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|August 9, 2022
COVID-19 and Therapeutic ApheresisSergey Tselmin, Ulrich Julius, Natalia Jarzebska, et al.
Journal of Cardiovascular Development and Disease|July 26, 2020
Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?Ulrich Julius, Solveig Kuss, Sergey Tselmin, et al.
Atherosclerosis. Supplements|December 11, 2019
Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresisSergey Tselmin, Ulrich Julius, Nadine Weinert, et al.
Atherosclerosis. Supplements|February 5, 2010
The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorptionUlrich Julius, Sergey Tselmin, Sabine Fischer, et al.
Journal of Clinical Medicine|November 13, 2021
Machine Learning Refutes Loss of Smell as a Risk Indicator of Diabetes MellitusJörn Lötsch, Antje Hähner, Peter E H Schwarz, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 30, 2022
The development of lipoprotein apheresis in Saxony in the last yearsSolveig Frieda Rosa Kuss, Ulrike Schatz, Sergey Tselmin, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|July 14, 2022
COVID-19 and Lipid DisordersUlrich Julius, Ulrike Schatz, Sergey Tselmin, et al.
Atherosclerosis. Supplements|November 4, 2017
Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulinsSergey Tselmin, Ulrich Julius, Stefan R Bornstein, et al.
Atherosclerosis. Supplements|November 4, 2017
How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single centerBernd Hohenstein, Sergey Tselmin, Stefan R Bornstein, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|September 2, 2022
Correction: COVID-19 and Therapeutic ApheresisSergey Tselmin, Ulrich Julius, Natalia Jarzebska, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|August 9, 2022
COVID-19 and Therapeutic ApheresisSergey Tselmin, Ulrich Julius, Natalia Jarzebska, et al.
Journal of Cardiovascular Development and Disease|July 26, 2020
Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?Ulrich Julius, Solveig Kuss, Sergey Tselmin, et al.
Atherosclerosis. Supplements|December 11, 2019
Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresisSergey Tselmin, Ulrich Julius, Nadine Weinert, et al.
Atherosclerosis. Supplements|February 5, 2010
The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorptionUlrich Julius, Sergey Tselmin, Sabine Fischer, et al.
Journal of Clinical Medicine|November 13, 2021
Machine Learning Refutes Loss of Smell as a Risk Indicator of Diabetes MellitusJörn Lötsch, Antje Hähner, Peter E H Schwarz, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 30, 2022
The development of lipoprotein apheresis in Saxony in the last yearsSolveig Frieda Rosa Kuss, Ulrike Schatz, Sergey Tselmin, et al.
Pageof 3